Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
25 hedge funds and large institutions have $3.61M invested in Hepion Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 7 closing their positions.
1,113% more call options, than puts
Call options by funds: $97K | Put options by funds: $8K
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
11% less funds holding
Funds holding: 28 → 25 (-3)
15% less capital invested
Capital invested by funds: $4.24M → $3.61M (-$631K)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$43.4K |
| 2 |
VF
Virtu Financial
New York
|
+$27.5K |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$17.1K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$13.4K |
| 5 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$6.72K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$235K |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$26K |
| 3 |
Jane Street
New York
|
-$23K |
| 4 |
BlackRock
New York
|
-$13.4K |
| 5 |
Two Sigma Advisers
New York
|
-$9.77K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IC
26
Ikarian Capital
Dallas,
Texas
| – | -$235K | -410 | Closed |
|
|
BFM
27
Boothbay Fund Management
New York
| – | -$26K | -45 | Closed |
|
|
28
Jane Street
New York
| – | -$23K | -40 | Closed |
|
|
AWA
29
Amplius Wealth Advisors
Blue Bell,
Pennsylvania
| – | -$5K | -10 | Closed |
|
30
Commonwealth Equity Services
Waltham,
Massachusetts
| – | -$5K | -10 | Closed |
|
|
GWM
31
Geneos Wealth Management
Englewood,
Colorado
| – | -$2K | -5 | Closed |
|
|
CS
32
Credit Suisse
Zurich,
Switzerland
| – | -$1K | -2 | Closed |
|
HEPA Hedge Fund Activity: Q3 2022 in Review
25 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q3 2022, worth a combined $3.61M — down 15% from $4.24M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of HEPA and 4 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Susquehanna International Group, adding an estimated $43.4K. The largest seller was Ikarian Capital, exiting entirely with an estimated $235K sold.
- 25 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q3 2022, down from 28 in Q2 2022.
- Funds reported $3.61M of Hepion Pharmaceuticals stock for Q3 2022, down 15% quarter-over-quarter.
- 4 funds opened new Hepion Pharmaceuticals positions in Q3 2022 and 7 closed out, a net change of -3 holders.
- The largest Hepion Pharmaceuticals buyer in Q3 2022 was Susquehanna International Group, an estimated $43.4K added.
- The largest Hepion Pharmaceuticals seller in Q3 2022 was Ikarian Capital, an estimated $235K sold.
Based on aggregated 13F filings for Q3 2022.